Rezdiffra (Resmetirom) Safety Signals and FDA Actions

FDA Regulatory Timeline and Approval Basis

The FDA granted accelerated approval to resmetirom on March 14, 2024, making it the first drug approved specifically for metabolic dysfunction-associated steatohepatitis (MASH), previously called NASH 1. The approval was based on a surrogate endpoint (NASH resolution without worsening fibrosis) rather than a direct clinical outcome like reduced mortality or liver transplantation. This distinction matters. Accelerated approval carries a legal obligation: Madrigal Pharmaceuticals must complete a confirmatory trial demonstrating actual clinical benefit, or the FDA can withdraw the indication.

The agency's decision followed a February 2024 advisory committee meeting where the Endocrinologic and Metabolic Drugs Advisory Committee voted 11-0 (with 1 abstention) in favor of approval, acknowledging both the unmet medical need and the limitations of the surrogate endpoint approach 2. The FDA label restricts the indication to patients with moderate to advanced fibrosis (F2-F3), excluding compensated cirrhosis (F4) patients due to insufficient safety and efficacy data in that population.

Resmetirom's approval pathway mirrors the conditional approvals seen in oncology, where tumor response rates serve as surrogates for survival. The difference here is that liver histology improvement, while biologically plausible as a predictor of reduced liver-related events, has not yet been validated as a surrogate endpoint by the FDA's own standards.

Mechanism of Action and Why It Matters for Safety

Resmetirom is an oral, liver-directed, selective agonist of thyroid hormone receptor beta (THR-beta) 3. THR-beta is the dominant thyroid hormone receptor isoform in hepatocytes, where it regulates lipid metabolism, mitochondrial function, and fatty acid oxidation. By selectively activating THR-beta over THR-alpha (the isoform concentrated in heart and bone), resmetirom aims to deliver the metabolic benefits of thyroid hormone signaling in the liver without causing tachycardia, bone loss, or other systemic hyperthyroid effects.

This selectivity is not absolute. Clinical trial data show modest effects on heart rate in some patients, and the long-term cardiovascular implications of chronic THR-beta agonism remain an open question that MAESTRO-OUTCOMES is designed to address 4. The drug undergoes extensive hepatic first-pass metabolism, which concentrates exposure in the target organ but also means that patients with significant hepatic impairment may have unpredictable drug levels.

A key pharmacological consideration: resmetirom lowers LDL cholesterol by 13-16% and triglycerides by 20-25% through increased hepatic lipid clearance 2. These lipid effects are therapeutically useful in a MASH population with high cardiovascular risk, but they also suppress thyroid-stimulating hormone (TSH) levels. In MAESTRO-NASH, TSH levels dropped below the lower limit of normal in approximately 10-13% of resmetirom-treated patients. While T3 and T4 levels remained largely stable, this TSH suppression complicates thyroid monitoring in patients with pre-existing thyroid disease.

MAESTRO-NASH Safety Data in Detail

The 54-week MAESTRO-NASH trial enrolled 966 patients with biopsy-confirmed NASH and fibrosis stages F1B through F3, randomized to resmetirom 80 mg, resmetirom 100 mg, or placebo 2. The safety population provides the most comprehensive dataset for evaluating resmetirom's adverse event profile.

Gastrointestinal events dominated the adverse event reporting. Diarrhea occurred in 27% of the 80 mg group and 33% of the 100 mg group, compared to 15% with placebo. Nausea affected 20% and 22% of the treatment arms respectively, versus 12% on placebo. Most GI events were mild to moderate and occurred early in treatment, with attenuation over 12-16 weeks. The discontinuation rate due to GI adverse events was approximately 5-6% across both dose groups.

Hepatic safety signals require particular scrutiny given that the drug targets a population with baseline liver disease. In MAESTRO-NASH, alanine aminotransferase (ALT) elevations greater than 3 times the upper limit of normal occurred in 2.4% of the 100 mg group versus 1.5% with placebo 5. Drug-induced liver injury (DILI) was reported in a small number of cases, though distinguishing drug-related hepatotoxicity from progression of underlying MASH presents a significant diagnostic challenge. The FDA label includes a warning about hepatotoxicity and recommends baseline liver function testing with periodic monitoring.

Gallbladder-related events emerged as a notable signal. Cholelithiasis and cholecystitis occurred at rates of approximately 3.5% in the resmetirom groups versus 1.8% with placebo. This finding is pharmacologically consistent with increased hepatic cholesterol secretion into bile, a downstream consequence of THR-beta activation. Patients with known gallbladder disease were not specifically excluded from the trial, and the label advises monitoring for signs and symptoms of gallbladder disorders.

Bone-related signals showed no clinically significant differences in bone mineral density changes between resmetirom and placebo groups over 54 weeks, supporting the THR-beta selectivity claim. Dual-energy X-ray absorptiometry (DEXA) substudies within MAESTRO-NASH showed mean changes from baseline within 1% at the lumbar spine and total hip 2.

Post-Marketing Safety Surveillance

Since the March 2024 approval, FDA Adverse Event Reporting System (FAERS) data have accumulated reports across the drug's early commercial use. The FDA has required Madrigal to conduct several post-marketing studies and commitments as conditions of the accelerated approval 5.

The most significant ongoing requirement is MAESTRO-OUTCOMES (NCT06272721), a cardiovascular and liver outcomes trial designed to confirm that histological improvement translates into reduced clinical events including all-cause mortality, liver transplant, progression to cirrhosis, and major adverse cardiovascular events (MACE). This trial is expected to enroll over 5,000 patients with follow-up extending to approximately 54 months.

Post-marketing case reports of hepatotoxicity have prompted the FDA to reinforce monitoring recommendations. Dr. Nikolaos Pyrsopoulos, a hepatologist at Rutgers New Jersey Medical School, has noted: "The challenge with resmetirom hepatotoxicity surveillance is that our patients already have elevated liver enzymes at baseline. We need pattern recognition, looking for acute, disproportionate rises in ALT relative to the patient's own trajectory, rather than relying on fixed thresholds" 6.

The FDA also required a study evaluating resmetirom in patients with Child-Pugh B and C hepatic impairment, as the current label restricts use to those with compensated liver disease. Early pharmacokinetic data suggest that decompensated cirrhosis significantly alters resmetirom exposure, potentially increasing both efficacy and toxicity in unpredictable ways.

Drug Interactions and Special Populations

Resmetirom's hepatic metabolism creates several clinically relevant drug interaction pathways. The drug is a substrate of CYP2C8 and, to a lesser extent, CYP3A4 5. Strong CYP2C8 inhibitors (such as gemfibrozil) are expected to increase resmetirom exposure and should be avoided. This is directly relevant because gemfibrozil is prescribed for hypertriglyceridemia, a common comorbidity in the MASH population.

Resmetirom also inhibits organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3, which affects the disposition of statins. The label recommends dose adjustments for rosuvastatin (maximum 20 mg daily) and atorvastatin when co-administered with resmetirom. Given that 40-60% of MASH patients are on statin therapy, this interaction has broad practical implications 7.

Pregnancy and lactation: Resmetirom is not recommended during pregnancy based on animal reproductive toxicity data showing embryofetal lethality at clinically relevant exposures. The drug's effects on fertility are unknown. Women of reproductive potential should use effective contraception during treatment.

Renal impairment: No dose adjustment is required for mild to moderate renal impairment. Resmetirom has not been studied in severe renal impairment (eGFR <30 mL/min/1.73 m²).

Pediatric use: Safety and efficacy have not been established in patients younger than 18 years. Pediatric MASH is a growing concern, but the current evidence base does not support off-label use in this population.

Comparison with Emerging MASH Therapies

Resmetirom's safety profile should be evaluated in context. No other FDA-approved MASH therapy existed before March 2024, but several agents are in late-stage development with different mechanisms and different safety concerns.

Semaglutide, studied in the ESSENCE trial for MASH, carries GI adverse events at even higher rates (approximately 40-45% nausea) but has an extensive safety database from its GLP-1 receptor agonist use in obesity and diabetes 8. Obeticholic acid (OCA), a farnesoid X receptor agonist, showed pruritus in up to 51% of patients in the REGENERATE trial and raised LDL cholesterol rather than lowering it, which contributed to FDA concerns about cardiovascular safety 9. The FDA issued a complete response letter for OCA in June 2023.

Dr. Zobair Younossi, chairman of the Global NASH Council, has stated: "Resmetirom's favorable lipid effects distinguish it from other MASH candidates. The LDL and triglyceride reductions are genuine therapeutic advantages in a population where cardiovascular disease, not liver failure, remains the leading cause of death" 10.

Lanifibranor (a pan-PPAR agonist) and survodutide (a dual GLP-1/glucagon receptor agonist) are both in Phase 3 trials with different safety profiles. The MASH therapeutic space is evolving rapidly, and combination regimens targeting multiple pathogenic pathways will likely define future treatment paradigms.

Monitoring Recommendations for Prescribers

Based on the FDA label and published expert consensus, the following monitoring protocol applies to patients on resmetirom 5.

Obtain baseline labs before initiating therapy: comprehensive metabolic panel (including ALT, AST, total bilirubin, alkaline phosphatase), lipid panel, TSH, free T4, and CBC. Repeat liver function tests at months 1, 3, 6, and every 6 months thereafter. TSH monitoring should occur at 3-month intervals for the first year, then annually if stable.

Any ALT elevation exceeding 5 times the upper limit of normal or any ALT rise accompanied by bilirubin elevation greater than 2 times the upper limit of normal should prompt immediate drug discontinuation and hepatology consultation. This threshold aligns with modified Hy's Law criteria, which carry a 10-50% risk of fatal DILI when met 11.

For gallbladder monitoring, routine imaging is not recommended, but patients should be counseled about symptoms of cholelithiasis and cholecystitis (right upper quadrant pain, post-prandial discomfort, fever). Patients with a history of gallstones may warrant a baseline abdominal ultrasound.

Counsel patients that diarrhea and nausea typically peak during weeks 1-4 and tend to improve by week 12-16. Starting at the 80 mg dose and titrating to 100 mg after 12 weeks may reduce early GI side effects, though this titration strategy was not formally studied in MAESTRO-NASH.

Unanswered Safety Questions

Several critical safety questions remain open. The 54-week MAESTRO-NASH data represent a limited exposure duration for a disease requiring years of treatment. Chronic THR-beta agonism over 5-10 years may produce effects not detectable in a 54-week trial, particularly regarding thyroid axis feedback, hepatocyte proliferation, and potential hepatocellular carcinoma risk in cirrhotic patients 12.

The exclusion of F4 (cirrhotic) patients from the key trial leaves a significant knowledge gap. MASH patients often progress to compensated cirrhosis during treatment, and the safety of continuing resmetirom in a patient who transitions from F3 to F4 fibrosis is not well characterized.

Immunogenicity data are not applicable to a small-molecule drug, but potential off-target effects on extrahepatic THR-beta (present in kidney and pituitary) remain a theoretical concern that long-term registries should address.

The FDA requires final results from MAESTRO-OUTCOMES by 2028. If the confirmatory trial fails to demonstrate clinical benefit on hard endpoints, the accelerated approval could be withdrawn, a scenario that has precedent with other accelerated approvals in hepatology and oncology. Prescribers should discuss this uncertainty with patients as part of informed consent, framing resmetirom as a therapy with strong biological rationale and promising histological data, but without definitive proof of long-term clinical benefit as of May 2026.